Table 1.
Comparison between group I and II patients as regard the main clinical features, ultrasonography and laboratory findings.
| Group I N = 30 | Group II N = 30 | P value | |
|---|---|---|---|
| Age (years) mean (SD) | 39 (5) | 40 (5.9) | 0.4 (NS)* |
| Gender (N & %) | |||
| Male | 17 (56.7%) | 12 (40%) | 0.3 (NS)# |
| Female | 13 (43.3%) | 18 (60%) | |
| Skin disease duration (years) mean (SD) | 7.7 (1.2) | 8.8 (3.0) | 0.31 (NS)* |
| Duration of arthritis (years) mean (SD) | – | 1.7 (0.7) | – |
| PASI score mean (SD) | 23 (4) | 19.5 (5.8) | 0.29 (NS)* |
| Clinical enthesitis and dactylitis (N & %) | Zero | 7 (23.3%) | 0.0005 (HS)# |
| DAS 28 score mean (SD) | – | 4.6 (1.8) | – |
| Steinbrockers score mean (SD) | – | 23.4 (10) | – |
| Ultrasonography of patients with entheseal abnormalities (N & %) | 10 (33.3%) | 14 (46.7%) | 0.19 (NS)# |
| Serum COMP (mg/ml) of patients with elevated levels | |||
| N & % | 22 (73.3%) | 26 (86.7%) | 0.20 (NS)# |
| Mean (SD) | 5.9 (3) | 6.8 (12) | 0.37 (NS)≠ |
| CRP (mg/ml) mean (SD) | 11.9 (4) | 24.5 (13) | 0.03 (S)≠ |
*
Unpaired t-test;
#
Chi-square test;
≠
Mann Whitney test;
Abbreviations: PASI, psoriasis area and severity index; DAS 28, Disease activity score 28; COMP, cartilage oligomeric matrix protein; CRP, C-reactive protein.